Featured Research

from universities, journals, and other organizations

Jefferson Researchers Use Gene Therapy To Treat Rare, Inherited Brain Disease

Date:
March 24, 1998
Source:
Thomas Jefferson University
Summary:
Scientists are hoping the treatment provides some relief for a young girl, and provides insights to future uses of gene therapy for other illnesses.

Scientists are hoping the treatment provides some relief for a young girl, and provides insights to future uses of gene therapy for other illnesses

Researchers at Jefferson Medical College are for the first time attempting to use gene therapy to treat Canavan disease, a rare, fatal metabolic brain disorder.

A team of neurosurgeons are treating a four-year-old Illinois girl at Thomas Jefferson University Hospital, Thomas Jefferson University, Philadelphia. The group includes Andrew Freese, M.D., Ph.D., associate professor of neurosurgery and director of neurosurgery research, Matthew During, M.D., professor of neurosurgery, Paola Leone, Ph.D., adjunct assistant professor of neurosurgery, and Giancarlo Barolat, M.D., professor of neurosurgery, as well as their colleagues there and at Yale University.

Canavan disease is an inherited neurological disorder characterized by spongy degeneration of the brain. It primarily affects children of Eastern European or Ashkenazi Jewish background. It is one of a group of genetic disorders called leukodystrophies that affect the growth of the myelin sheath of the nerve fibers in the brain. The myelin sheath is the fatty covering surrounding the nerve cells that acts as an insulator. The disease is caused by a genetic flaw in which an enzyme fails to be produced. The disease is incurable, resulting in the over-production of a toxic compound in the brain, N-acetyl-aspartate (NAA). Death usually occurs between the ages of 5 and 7.

Symptoms of Canavan disease, which appear in early infancy and progress quickly, may include mental retardation, loss of previously acquired motor skills, difficulty feeding, abnormal muscle tone, poor head control, and an abnormally enlarged head. As time progresses, sufferers also become paralyzed, blind, and lose hearing and their interaction with the outside world.

"Children fail to meet normal developmental milestones," Dr. Freese explains. "Within a few years, they cannot feed themselves, walk, or see well." Dr. Freese says that the disease is similar to Tay-Sachs disease in that both are metabolic disorders causing the buildup of toxic compounds that affect normal brain development.

According to Dr. Freese, three years ago, his colleagues at Yale were contacted by Canavan families for their expertise in gene therapy to see about the possibility of developing a therapy for the disease. Drs. During, Leone and Freese developed a gene delivery system based on liposomes and polymers, rather than viruses, to deliver the genetic information for the enzyme into the brain.

They have shown that the system works in the lab and in animals. They then showed in preliminary studies in New Zealand that the Canavan gene could effectively be delivered into the brains of two children with Canavan disease, based on evidence of nerve myelination and on behavioral studies. They have gained federal Food and Drug Administration approval, Dr. Freese notes, to expand the work into a larger Phase 1 clinical trial.

To date, the Jefferson team plans to treat four Canavan disease children.

The therapy will consist of a ventricular catheter implanted under the scalp, allowing access to the brain's ventricles and cerebrospinal fluid, and to allow possible additional treatment. The Jefferson researchers are collaborating with specialists at Children's Hospital of Philadelphia to monitor myelin and enzyme levels using magnetic resonance spectroscopy and magnetic resonance imaging. "We'll also look at behavioral aspects of the children--a whole battery of tests before and after gene therapy," Dr. Freese points out.

"We anticipate expanding our gene therapy approach to other inherited metabolic disorders, such as Krabbe disease," he notes, together with David Wenger, Ph.D., professor of medicine at Jefferson Medical College, who leads the Lysosomal Disease Testing Laboratory. "We hope to set up a clinical trial for that within the next year as well."

He cautions that few patients have been treated this way as yet.

"They [results from this trial] may give us some information about the possibility of treating other neurological disorders, such as other inherited diseases, and Parkinson's disease, stroke and epilepsy," he concludes.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Jefferson Researchers Use Gene Therapy To Treat Rare, Inherited Brain Disease." ScienceDaily. ScienceDaily, 24 March 1998. <www.sciencedaily.com/releases/1998/03/980324074738.htm>.
Thomas Jefferson University. (1998, March 24). Jefferson Researchers Use Gene Therapy To Treat Rare, Inherited Brain Disease. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/1998/03/980324074738.htm
Thomas Jefferson University. "Jefferson Researchers Use Gene Therapy To Treat Rare, Inherited Brain Disease." ScienceDaily. www.sciencedaily.com/releases/1998/03/980324074738.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins